Lexeo Therapeutics (NASDAQ:LXEO) Issues Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO) posted its earnings results on Monday. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09, Zacks reports.

Lexeo Therapeutics Stock Up 50.9 %

Shares of NASDAQ:LXEO opened at $4.09 on Tuesday. The company has a 50 day moving average of $4.15 and a 200-day moving average of $6.71. Lexeo Therapeutics has a one year low of $2.32 and a one year high of $19.50. The stock has a market cap of $135.24 million, a price-to-earnings ratio of -1.29 and a beta of 3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Leerink Partners lowered their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.60.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.